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Differential expression of the fractalkine chemokine
receptor (CX3CR1) in human monocytes during
differentiation
Cecilia Analia Panek1, Maria Victoria Ramos1, Maria Pilar Mejias1, Maria Jimena Abrey-Recalde1,
Romina Fernandez-Brando1, Maria Soledad Gori2, Gabriela V Salamone2 and Marina S Palermo; 1
Circulating monocytes (Mos) may continuously repopulate macrophage (MAC) or dendritic cell (DC) populations to
maintain homeostasis. MACs and DCs are specialized cells that play different and complementary immunological
functions. Accordingly, they present distinct migratory properties. Specifically, whereas MACs largely remain in tissues,
DCs are capable of migrating from peripheral tissues to lymphoid organs. The aim of this work was to analyze the
expression of the fractalkine receptor (CX3CR1) during the monocytic differentiation process. Freshly isolated Mos
express high levels of both CX3CR1 mRNA and protein. During the Mo differentiation process, CX3CR1 is downregulated
in both DCs and MACs. However, MACs showed significantly higher CX3CR1 expression levels than did DC. We also
observed an antagonistic CX3CR1 regulation by interferon (IFN)-c and interleukin (IL)-4 during MAC activation through
the classical and alternative MAC pathways, respectively. IFN-c inhibited the loss of CX3CR1, but IL-4 induced it.
Additionally, we demonstrated an association between CX3CR1 expression and apoptosis prevention by soluble
fractalkine (sCX3CL1) in Mos, DCs and MACs. This is the first report demonstrating sequential and differential CX3CR1
modulation during Mo differentiation. Most importantly, we demonstrated a functional link between CX3CR1 expression
and cell survival in the presence of sCX3CL1.
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INTRODUCTION
Monocytes (Mos) represent approximately 5%–10% of peri-
pheral blood leukocytes in humans and mice. They originate
from a myeloid precursor in the bone marrow,1 are released
in the circulation and then enter into tissues. The half-life of
Mo in blood is believed to be relatively short: approximately 3
days in humans.2 This short half-life in the blood has fostered
the concept that blood Mo may continuously repopulate macro-
phage (MAC) or dendritic cell (DC) populations to maintain
homeostasis and, during inflammation, fulfill critical roles in
innate and adaptive immunity.3,4 Two major fates of Mo differ-
entiation are easily identified and separable: many Mos develop
into MACs, and others become DCs.5 Functionally, MACs
robustly degrade material that they engulf6 and apparently fail
to present antigens or initiate a T-cell response,7,8 release a vari-
ety of cytokines upon activation and are thought to be impor-
tant for the local clearance of dead cells in inflamed and non-
inflamed tissues.9 In contrast, DCs have a poor proteolytic capa-
city,6 but are able to phagocytize material from other cells and
to process and intracellularly retain peptides/antigens that are
subsequently presented by major histocompatibility complex
molecules together with appropriate costimulation for T-cell
priming.8,10
Moreover, MACs and DCs have distinct migratory pro-
perties. Whereas MACs largely remain in tissues, DCs are ca-
pable of migrating from peripheral tissues to lymphoid organs
to interact with T cells and induce an immune response.11 In
this regard, recent research has focused on the mechanisms and
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molecules involved in monocyte recruitment and their differ-
entiation in various tissues.12,13
Fractalkine (CX3CL1), a member of the CX3C subfamily, is a
unique chemokine in which the first two conserved cysteine
residues are separated by three non-conserved amino acids.14
Unlike other chemokines, CX3CL1 exists in two forms: a mem-
brane-anchored form and a soluble form. Soluble CX3CL1
(sCX3CL1) acts as a chemoattractant, whereas the membrane-
anchored molecule functions as an adhesion molecule. The
membrane anchored form of CX3CL1 includes a chemokine
domain that is tethered to the cell surface via a heavily glyco-
sylated mucin-like stalk, followed by a single transmembrane
domain and a single cytoplasmic domain.15,16 The full-length
molecule can be cleaved from the cell membrane by tumor
necrosis factor-a-converting enzyme, a member of the ADAM
(disintegrin and metalloprotease) family, and ADAM10, to pro-
duce a soluble form that includes the chemokine domain and
most of the stalk region.15 CX3CL1 is expressed on the surface
of endothelial cells,17 epithelial cells,17,18 DCs19,20 and neurons21
and is induced by pro-inflammatory cytokines, such as inter-
leukin (IL)-1 and tumor necrosis factor-a.22,23 The CX3CL1
receptor, CX3CR1, is capable of mediating both leukocyte
migration and firm adhesion. CX3CR1 is expressed on a num-
ber of leukocytes, including monocytes, T-cell subsets and NK
cells,24,25 and CX3CR1 expression has been recently described in
platelets.26 However, a comprehensive knowledge about
CX3CR1 expression during monocyte differentiation and the
intracellular signals and pathways that underlie this process
have not been explored.
The most popular model to study monocyte-derived DCs is
to culture blood Mo of either subset27 in the presence of gran-
ulocyte-macrophage colony stimulating factor (GM-CSF) and
IL-45,28 or other related cytokine cocktails.29 These DCs have
been considered the ‘gold standard’ DC30 for assessing matura-
tion and many aspects of human DC biology. Conversely,
although a body of evidence suggests that MACs in several
organs self-renew without input from blood precursors,13 the
fact that Mos give rise to MACs in virtually any organ in the
context of inflammation is undisputed. In this regard, GM-CSF
is the growth factor that is traditionally used to differentiate
Mos into MACs.31,32
In the current study, we investigated CX3CR1 expression in
circulating Mos, Mo-derived DCs or MACs using different in
vitro cytokine stimulation by monitoring the phenotype of these
cells at different stages in culture. Furthermore, CX3CR1 regu-
lation at the transcriptional level was evaluated by mRNA ana-
lysis during Mo differentiation. Finally, the biological relevance




Endotoxin-free reagents and plastics were used in all experi-
ments. Lipopolysaccharide (LPS, Escherichia coli serotype
O111:B4), acridine orange, ethidium bromide and propidium
iodide (PI) were obtained from Sigma (St Louis, MO, USA).
Soluble fractalkine (sCX3CL1) was obtained from PeproTech
(Mexico, DF, Mexico). FITC-conjugated anti human-CX3CR1
mAb (Clone 2A9-1)—Rat IgG2b, k—were from BioLegend
(San Diego, CA, USA); PC5-conjugated anti human-CD14
mAb (Clone RMO52)—Mouse IgG2a—were from Beckman
Coulter (Brea, CA, USA); R-phycoerythrin-conjugated anti
human-CD16 mAb (Clone 3G8)—Mouse IgG1, k—were from
CALTAG Laboratories (Burlingame, CA, USA), PE-conjugated
anti-human CD23 mAb (Clone M-L233)—Mouse IgG1, k—,
PE-CY5-conjugated anti-human CD86 mAb (Clone IT2.2)—
Mouse IgG2b, k—, PE-conjugated anti human-CD83 mAb
(Clone HB15e)—Mouse IgG1, k—, FITC-conjugated anti-
human-CD1a mAb (Clone HI149)—Mouse IgG1, k—, FITC-
conjugated anti-human—human leukocyte antigen (HLA)-DR
mAb (Clone L243)—Mouse IgG2a, k—, FITC-conjugated anti
human-CD206 mAb (Clone 19.2)—Mouse IgG1, k—were
from BD Pharmingen (San José, CA, USA); PE-conjugated anti
human-CCR2 mAb (Clone 48607)—IgG2B—were from R&D
Systems (Minneapolis, MN, USA); Recombinant human IL-4,
recombinant human IL-13 and recombinant human interferon
(IFN)-c were from PeproTech. GM-CSF was from Laboratorios
Goutier (Laboratorios Goutier S.A., Ciudad de Buenos Aires,
Argentina).
Human peripheral blood Mo isolation and culture
Mos were isolated from freshly prepared buffy coats that were
2–4 h old and were kindly provided by the Garrahan Hospital’s
Hemotherapy Service (Ciudad de Buenos Aires, Argentina).
Blood samples were obtained from healthy donors after written
informed consent was obtained. Briefly, peripheral blood
mononuclear cells were obtained by standard density gradient
centrifugation on Ficoll-Hypaque (Ficoll Pharmacia, Uppsala,
Sweden; Hypaque, Wintthrop Products, Buenos Aires,
Argentina). Subsequently, Mos were further isolated using a
Percoll (GE Healthcare, Uppsala, Sweden) gradient centrifu-
gation, as previously described.33 Mo viability was .96%, as
determined by the trypan blue exclusion test, and CD14 stain-
ing of Mo revealed that their purity was .85%. Finally, Mos
were suspended at 106/ml in RPMI-1640 (Hyclone Laboratories
Inc., Logan, UT, USA) supplemented with 10% heat-inacti-
vated fetal calf serum (FCS) (Natocor, Córdoba, Argentina),
and antibiotic–antimycotic liquid (Gibco, Invitrogen, San
Diego, CA, USA).
Human DCs and MAC preparation
Mos were purified as described above (purity.85%) and cul-
tured up to 7 days at a concentration of 13106/ml in complete
RPMI media that was supplemented with 30 ng/ml GM-CSF to
differentiate the cells into MACs or with 50 ng/ml GM-CSF and
20 ng/ml IL-4 or IL-13 to differentiate the cells into immature
DCs (iDCs) in six-well culture plates (Corning Inc., New York,
NY, USA) with or without 1000 U/ml IFN-c. On day 3, fresh
media containing the growth factors were added. On day 7, the
cells were harvested, washed twice with PBS, and either used for
the experiments or aliquoted for further differentiation. Where
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indicated, iDCs were further cultured in the presence of 500 ng/
ml LPS11000 U/ml IFN-c for 48 h to induce maturation.
Unless indicated otherwise, MACs were polarized with
400 U/ml IFN-c1100 ng/ml LPS for M1 differentiation or
25 ng/ml IL-4 alone for M2 differentiation in complete RPMI
media for 3 additional days.34
Cellular apoptosis quantification by Annexin-V binding and
flow cytometry
Mos were purified as described above and cultured overnight at
a concentration of 1.53106/ml in complete RPMI medium that
was supplemented with 1% FCS. An aliquot of purified Mo was
cultured for 7 days in RPMI medium that was supplemented
with 30 ng/ml GM-CSF to differentiate the cells into MACs or
with 50 ng/ml GM-CSF and 20 ng/ml IL-4 to differentiate the
cells into iDCs in six-well culture plates (Corning Inc.). On the
last day, medium containing growth factors was removed and
replaced with RPMI medium that was supplemented with 1%
FCS with or without 1 mg/mL sCX3CL1. After 24 h, the cells
were harvested, washed twice with PBS, and used for cellular
apoptosis quantification. Annexin-V binding to cells was per-
formed using an apoptosis detection kit (APOAF 50TST;
Sigma). In brief, the cells were labeled with annexin-V-FITC
for 15 min at 4 uC and with PI immediately before the evalu-
ation of fluorescence by flow cytometry (FACScan flow cyt-
ometer; Becton Dickinson, San Jose, CA, USA). The collected
data were analyzed using the CellQuest analysis software
(Becton Dickinson), as previously described. The results are
reported as a percentage of Annexin-V-positive cells.
Quantification of cellular apoptosis and viability by
fluorescent microscopy
Quantification of Mo apoptosis after overnight incubation
with or without sCX3CL1 was performed as previously
described using the fluorescent DNA-binding dyes acridine
orange (100 mg/ml) to determine the percentage of Mo that
had undergone apoptosis and using ethidium bromide
(100 mg/ml) to differentiate between viable and nonviable
cells.35 To assess the percentage of Mo showing morphological
features of apoptosis, at least 200 cells were scored in each
experiment.
Flow cytometric analysis
Mos were identified and gated according to their side vs. for-
ward scattering (SSC/FSC) dot-plot profiles and positive stain-
ing for CD14. Each cell population was incubated with a
specific conjugated mAb for 30 min at 4 uC. In all cases, iso-
type-matched antibodies were assayed in parallel, and the
threshold level for the fluorescence of positive cells was set
for each sample based on the difference between the curves
obtained from the specific and isotype control mAb stainings< .
The fluorescence was measured on 10 000 events using the Cell
Quest program on a Becton Dickinson FACScan, and the
results were expressed as percentage of positive cells for each
antigen.
RNA isolation and quantitative real-time reverse
transcriptase-polymerase chain reaction (qRT-PCR)
Total RNA was obtained from fresh Mos after purification and
from iDCs at 72 h of culture during differentiation. Total RNA
from MACs was obtained after differentiation at day 7, and
total RNA from M1 or M2 polarized MACs was extracted at
day 10, which included 7 days of differentiation and 3 days of
polarization.
Total RNA was extracted with the NucleoSpin RNA II Kit
(Macherey-Nagel, Bethlehem, PA, USA) from 53106 Mos or
33106 Mo-derived DCs or MACs from healthy blood donors.
For each sample, cDNA was synthesized from 1 mg of total RNA
(pre-treated with DNaseI during extraction) with the
Accuscript High Fidelity 1st Strand cDNA synthesis kit
(Stratagene, La Jolla, CA, USA) according to the manufac-
turer’s instructions. Relative quantification of CX3CR1 and
the housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) mRNA expression was measured by qRT-
PCR using a LightCycler 2.0 instrument with the Fast-Start
DNA Master SYBR Green I real-time PCR kit, according to
the manufacturer’s instructions (Roche Applied Science,
Indianapolis, IN, USA).
PCR amplifications were performed in a final volume of
20 ml, which contained 4 mM MgCl and 0.75 mM of each of
the required primers. PCR was performed with an initial dena-
turation step of 10 min at 95 uC, followed by 45 cycles of a qRT-
PCR protocol (10 s at 95 uC, 10 s annealing at 58 uC and 15 s
extension at 72 uC). The SYBR Green fluorescent DNA binding
dye was monitored after each cycle at 81 uC. The LightCycler
2.0 was used to determine the crossing point for individual
samples. Serial dilutions of a positive control sample of
cDNA were prepared in duplicate to generate standard curves.
Relative standard curves describing the PCR efficiency of target
gene and GAPDH were created and used to perform efficiency-
corrected quantification with the LightCycler Relative
Quantification Software version 4.0. The results were expressed
as a concentration ratio between the target gene and the
GAPDH mRNA levels. Products were not generated in control
reactions in which reverse transcriptase was omitted during
cDNA synthesis.
The primers were V28 CX3CR1: forward 59-TGACTGGCA-
GATCCAGAGGTT-39, reverse 59-GTAGAATATGGACAGG-
AACAC-39 (product size 163 bp);36 GAPDH: forward 59-CCC-
TTCATTGACCTCAACTAC-39, reverse 59-TGAGTCCTTCC-
ACGATACC-39 (product size: 416 bp).37
To check the primer specificity, the PCR products were elec-
trophoresed on 2% agarose gels and visualized with ethidium
bromide staining.
Statistical analysis
Statistical significance between more than two groups was
tested using the non-parametric, one-way Kruskal–Wallis test.
Comparative analyses between two groups were performed
using the non-parametric, unpaired, two-tailed Mann–
Whitney U test.
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RESULTS
Freshly isolated Mos downregulate CX3CR1 during culture
As previously described,38 the loss of CX3CR1 expression dur-
ing ON culture was observed in Mos that were purified from
buffy coats or peripheral blood both in the presence of FCS or
autologous serum, which allowed us to rule out artificial activa-
tion that was derived from the purification procedure.
During incubation, the Mos underwent changes in both
morphology and surface antigen expression, depending on
the culture conditions. Freshly isolated Mos initially appeared
small and round, but after 7 days in GM-CSF-conditioned
medium, they became adherent and increased in both size
and granularity. In contrast, Mos cultured in GM-CSF1IL-
4 conditioned medium for 7 days became large cells and grew
in multiple semi-adherent colonies and exhibited cytoplasmic
projections. These morphological changes were also observed
in the different dot plot graphic of FSC vs. SSC profiles by
flow cytometry (Figure 1a). Next, we analyzed the CD14,
CD16 and CD1a cell marker expression patterns (Figure 1a
and b). We observed that Mos that were cultured with GM-
CSF (30 ng/ml) for 7 days upregulated CD16 expression and
downregulated CD14 expression, which was consistent with a
change in the phenotype from Mo to MAC. In contrast, Mos
cultured with GM-CSF (50 ng/ml)1IL-4 (20 ng/ml) for 7
days, downregulated CD14 and upregulated CD1a, consistent
with a change in phenotype from Mos to iDCs (Figure 1a and
b). Next, we analyzed whether CX3CR1 expression was
altered during Mo differentiation into either MACs or
iDCs. Freshly isolated Mos had high CX3CR1 expression,
which was completely lost after 7 days of incubation in
DC-differentiating conditions (Figure 1c and d). It is impor-
tant to note that CX3CR1 expression was significantly down-
regulated at 24 h and that by 72 h, no CX3CR1 was found on
the iDC surfaces (Figure 1e). At this time point, the CD1a
differentiation marker began to rise, and the expression of
CD14 was partially downregulated.
In contrast, MAC CX3CR1 expression after 7 days of culture
was higher than that observed at day 1 of culture, although at
this time point, CD16 began to rise and CD14 was partially
downregulated (data not shown). However, despite the partial
restoration of CX3CR1 expression in MACs after 7 days of
culture in the presence of GM-CSF, the percentage of MACs
that were positive for CX3CR1 was lower than in the fresh Mo
(Figure 1e).
These data indicate that CX3CR1 is differentially expressed
on human Mos, MACs and DCs and that one consequence of
monocyte differentiation towards DCs is the selective loss of
CX3CR1 protein from the cell surface.
DC maturation
Based on the above results, we decided to further examine
the regulation of CX3CR1 expression during DC maturation.
Mature DCs (mDCs) were induced by treatment of iDCs
with 500 ng/ml LPS11000 U IFN-c for 48 h. The results
showed that the mDCs were characterized by increased
HLA-DR, CD86 and CD83 expression compared with iDCs
(Figure 2a and b). CD86 molecule expression represents
the main co-stimulatory axis for immune reactions. The
induction of high CD83 and HLA-DR levels in mature
DCs simply shows that they are functional.39 Even after this
maturation process, CX3CR1 expression remained negligible
in the DC population (Figure 2c).
Alternative protocol for Mo differentiation towards iDCs
Although the most common differentiation protocol of human
Mos towards DCs uses GM-CSF plus IL-4, some groups have
reported that IL-13 can also differentiate Mos into DCs equally
or even more efficiently than IL-4.40 Both cytokines have struc-
tural and functional similarities.41 The results depicted in sup-
plemental Figure 1a confirm that IL13 plus GM-CSF was
efficient in differentiating Mos into iDCs and that the induced
phenotype was similar to IL-4-driven iDCs.
Under this alternative differentiation protocol, the iDCs
showed no CX3CR1 membrane expression from day 3 of cul-
ture (Supplementary Figure 1b). In conclusion, during the dif-
ferentiation process to DCs, Mos lose CX3CR1 from their
cellular membranes and expression cannot be restored by ma-
turation stimuli.
Classical and alternative activation of MACs differentially
affects CX3CR1 expression
The above data indicate that CX3CR1 is differentially expressed
on MACs and DCs. The differential cytokine composition
between both culture conditions was IL-4 (or IL-13), which
was present in the DC differentiation medium. The effects of
IL-4 (or IL-13) on MACs have been a major focus of immu-
nologists. When MACs are stimulated with IL-4 (or IL-13) in
the absence of IFN-c (and/or TLR ligands), a distinct pattern of
gene expression, cell surface markers, secreted cytokines and
chemokines occurs relative to those induced by IFN-c (6TLR
ligands) stimulation. Gordon and Taylor13 described the for-
mer as ‘alternative activation’ of MACs to distinguish it from
the latter, ‘‘classical activation’’.42 Therefore, we determined
CX3CR1 expression following MAC activation by culturing
these cells for 72 h in the presence of 25 ng/ml of IL-4 to drive
‘alternative activation’ (M2) or 100 ng/ml LPS1400 U/ml IFN-
c to drive classical activation (M1).13 Flow cytometry analysis
revealed that MACs treated with IFN-c1LPS upregulated the
MAC maturation marker HLA-DR and downregulated
CD206, confirming the M1 phenotype (Figure 3a and b).
Conversely, IL-4 treatment induced enhanced CD206 and
HLA-DR expression.42 Additionally, these cells expressed
CD23 antigen, which is specifically induced by IL-4. Finally,
we analyzed CX3CR1 expression in both types of activated
MACs by flow cytometry. The results in Figure 3c and d show
that IL-4 induced the downregulation of CX3CR1 membrane
expression on MACs. In contrast, MACs that were classically
differentiated in the presence of LPS1IFN-c for 72 h upregu-
lated CX3CR1 expression. Altogether, these results strongly
suggest that classical and alternative MAC activation antagon-
istically modulates CX3CR1 expression.
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Figure 1 CX3CR1 expression changes in different Mo-derived populations. Freshly isolated Mos were either immediately stained or after culturing
for 7 days with GM-CSF (30 ng/ml) or GM-CSF (50 ng/ml)1IL-4 (20 ng/ml) to differentiate Mos into MACs or iDCs, respectively. Cells were stained
with fluorescein isothiocyanate PC5-conjugated anti-CD14 mAb, PE-conjugated anti-CD16 mAb and FITC-conjugated anti-CD1a mAb. (a)
Morphology changes between freshly isolated Mos, iDCs and MACs were determined by flow cytometric analysis of scatter (SSC) vs. forward
(FSC). A representative dot plot of each cellular population according to the culture condition is shown in the left panel. Flow cytometric analysis of
the cell surface expression of CD14, CD16 and CD1a was performed by gating the monocytic, iDC or MAC populations according to size and
granularity in the SSC vs. FSC dot plot. Representative histograms of membrane expression of each antigen marker in the Mo, iDC and MAC
populations are shown in the right panel. Dotted histograms represent the isotype controls. (b) The percentage of CD14-, CD16- and CD1a-positive
cells in the freshly isolated Mos, iDCs and MACs are shown. Each bar represents the mean6s.e.m. from 5–10 different donors. **P,0.01 and
***P,0.001, by the Kruskal–Wallis test (P,0.001) followed by the Mann–Whitney U test were calculated for each marker individually. Mos, iDCs
or MACs were also stained with a FITC-conjugated anti-CX3CR1 mAb. Cells were analyzed for CX3CR1 expression changes by flow cytometry. (c)
Representative histograms of membrane CX3CR1 expression in Mos, iDCs and MACs are shown. Dotted histograms represent the isotype controls.
(d) The percentages of CX3CR1 positive cells in Mo, iDC and MAC populations are shown. Each bar represents the mean6s.e.m. from 7–10
different donors. ***P,0.001, according to the Kruskal–Wallis test followed by the Mann–Whitney U test. (e) Changes in CX3CR1 expression at
different culture times. Each bar represents the mean6s.e.m. from 4–10 different donors. **P,0.01, by the Kruskal–Wallis test (P,0.001)
followed by the Mann–Whitney U test. iDC, immature dendritic cell; MAC, macrophage; Mo, monocyte; PC5, phycoerythrin–cyanin 5.1; PE,
phycoerythrin.
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Presence of IFN-c during DC differentiation abrogated
CX3CR1 downregulation
Because MACs activated in the presence of IFN-c upregulated
CX3CR1 expression, we further investigated whether IFN-c
was able to abrogate the loss of CX3CR1 during DC differenti-
ation. Mos were incubated with IFN-c (1000 U/ml) from the
first until the third day of the DC-differentiating protocol.
Figure 2d shows that DCs differentiated in the presence of
IFN-c inhibited the downregulation of CX3CR1. In contrast,
we previously showed that iDCs that maturated for 48 h in the
presence of IFN-c1LPS did not reverse the CX3CR1 down-
regulation that occurred during DC differentiation. These
results suggest that IFN-c was able to attenuate CX3CR1 down-
regulation during the first stages of DC differentiation and
induced its expression in MACs.
CX3CR1 gene expression in Mos, MACs and DCs
Because we established that CX3CR1 protein was differentially
regulated during Mo differentiation into DCs or MACs, we
next determined whether this regulation occurs at the tran-
scription level. For this purpose, CX3CR1 mRNA expression
was analyzed by reverse transcription coupled with qRT-PCR.
Using primers specific for the CX3CR1 V28 variant, we
obtained a 163 bp PCR product from freshly isolated Mos
(Figure 4a). Thus, we performed a quantitative analysis of
CX3CR1 mRNA on freshly isolated Mos, Mos cultured for 3
days in GM-CSF1IL-4/IL-13, Mos cultured for 7 days in GM-
CSF and MACs polarized for 3 additional days with IFN-
c1LPS or IL-4. Under these conditions, the freshly isolated
Mos showed high CX3CR1 mRNA levels that were drastically
decreased during DC or MAC differentiation. Consistent with
the CX3CR1 membrane expression, CX3CR1 mRNA in MACs
was higher than in DCs. Interestingly, we still detected CX3CR1
mRNA in DCs, whereas CX3CR1 protein was undetectable.
Conversely, the further IL-4-dependent alternative activation

































































Figure 2 CX3CR1 expression in DC after maturation. Mo-derived iDC
were further cultured in presence of LPS (500 ng/ml)11000 U/ml de
IFN-c for 48 h to obtain mDC. Subsequently, the cells were stained with
FITC-conjugated anti-CD1a mAb, PE-conjugated anti-CD83 mAb, PE-
Cy5-conjugated anti-CD86 mAb and FITC-conjugated anti-HLA-DR
mAb and then analyzed by flow cytometry. (a) Representative histo-
grams for CD1a, CD83, CD86 and HLA-DR membrane expression in
iDC or mDC are shown. Dotted histograms represent the isotype con-
trols. (b) The percentages of positive cells for CD1a, CD83, CD86 and
HLA-DR in iDC or mDC are shown. Each bar represents the mean6-
s.e.m. from 4–6 different donors. *P,0.05 and **P,0.01, by Mann–
Whitney U test calculated for each marker individually. (c) CX3CR1
expression in Mo, iDC or mDC. The results are expressed as percentage
of positive cells. Each bar represents the mean6s.e.m. from 7–10 dif-
ferent donors. ***P,0.001, according to Kruskal–Wallis test
(P,0.001) followed by the Mann–Whitney U test. (d) Mo were cultured
up to 3 days in the presence of GM-CSF (50 ng/ml)1IL-4 or IL-13 (20 ng/
ml) with or without IFN-c (1000 U/ml). Subsequently, the cells were
stained with FITC-conjugated anti-CX3CR1 mAb and then analyzed by
flow cytometry. The percentages of CX3CR1 positive cells in every cell
population are shown. Each bar represents the mean6s.e.m. from 2–4
different donors. DC, dendritic cell; GM-CSF, granulocyte-macrophage
colony stimulating factor; HLA, human leukocyte antigen; IFN, inter-
feron; LPS, lipopolysaccharide; mDC, mature dendritic cell; PE, phy-
coerythrin.
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of MACs downregulated CX3CR1 mRNA (Figure 4b).
Altogether, these results suggest that the decrease in CX3CR1
protein expression was concomitant with the downregulation
of CX3CR1 mRNA.
Biological function of the CX3CR1–CX3CL1 interaction
Finally, to assess the biological impact of the differences in
CX3CR1 expression on the Mo-derived populations, we inves-
tigated sCX3CL1-dependent survival in fresh Mos, iDCs and
MACs because the CX3CR1–CX3CL1 interaction has been
previously proposed to be a signal for Mo survival.43
Morphological assessment of Mo apoptosis showed a signifi-
cant decrease in the apoptotic rate of Mo cultured overnight
with sCX3CL1 compared with control Mos that were incubated
in medium (Figure 5a). Because 1 mg/ml of CX3CL1 was suf-
ficient to significantly delay Mo apoptosis, this concentration
of ligand was used in the following experiments.
A similar result was observed by flow cytometry through
DNA staining with PI and binding of phosphatidylserine on
the cell surface by annexin-V (Figure 5b). Thus, the percentage
of annexin V-positive Mos significantly decreased, and PI/
annexin V double-negative cells significantly increased in the
presence of sCX3CL1. However, there was no difference in the
apoptotic rate of iDCs when they were incubated overnight
with or without sCX3CL1 (Figure 5b). When MACs were simi-
larly treated with sCX3CL1, a slight but not significant decrease





























































Figure 3 CX3CR1 membrane expression in MACs before and after activation. MACs were further cultured for 72 h either in presence of LPS
(100 ng/ml)1IFN-c (400 U/ml) to obtain classically activated MACs (M1) or IL-4 (25 ng/ml) to obtain alternative-differentiated MACs (M2).
Subsequently, the cells were stained with FITC-conjugated anti-CD206 mAb, PE-conjugated anti-CD23 mAb, PCy5-conjugated anti-CD86 mAb
and FITC-conjugated anti-HLA-DR mAb and then analyzed by flow cytometry. (a) Representative histograms of membrane surface marker
expression in MAC, M1 and M2 cell populations are shown. Dotted histograms represent the isotype controls. (b) The percentage of positive cells
for CD206, CD23, CD86 and HLA-DR in MAC, M1 and M2 cell populations are shown. Each bar represents the mean6s.e.m. from 4–9 different
donors. *P,0.05, **P,0.01 and ***P,0.001, by the Kruskal–Wallis test (P,0.05) followed by the Mann–Whitney U test. In another set of
experiments, MAC, M1 and M2 populations were stained with FITC-conjugated anti-CX3CR1 mAb. (c) Representative histograms for CX3CR1
membrane expression in the MAC, M1 and M2 cell populations are shown. Dotted histograms represent the isotype controls. (d) The percentage of
CX3CR1-positive cells in the MAC, M1 and M2 cell populations are shown. Each bar represents the mean6s.e.m. from 9–12 different donors.
**P,0.01 and ***P,0.001, by the Kruskal–Wallis test (P,0.0001) followed by the Mann–Whitney U test. HLA, human leukocyte antigen; IFN,
interferon; LPS, lipopolysaccharide; MAC, macrophage; PE, phycoerythrin.
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in the apoptotic rate was observed (Figure 5b). These results
indicate that the interaction of sCX3CL1 with its receptor is in
fact an efficient survival signal and suggest that the differential
expression of this receptor in the cell membrane offers the
possibility to differentially regulate the half-life of Mo-derived
cells.
DISCUSSION
Considerable evidence suggests a major role for the CX3CR1–
CX3CL1 axis in Mo–endothelium interactions under physio-
logical or inflammatory conditions. However, little is known
about the regulation of CX3CR1 at different stages during mono-
cytic differentiation and maturation. CX3CL1 is prominently
expressed by multiple non-hematopoietic cell types, including
muscle, neurons, renal cells, epithelial and endothelial cells,
under inflammatory and pathological conditions.15,23,44–50
Under those conditions, CX3CL1 may facilitate the adhesion
and transmigration of monocytes.51 Additionally, it has been
recently proposed that a direct and evolutionary conserved role
for CX3CR1–CX3CL1 interactions is involved in Mo survival.
43
Although chemokines were originally defined as chemoattrac-
tants, a growing body of evidence indicates their additional
involvement in the control of cell survival.52 Landsman
et al.43 suggested that CX3CR1-survival signals can provide a
mechanistic explanation for one of the few known phenotypes
of CX3CR1- and CX3CL1-deficient mice (i.e., their relative
protection from diet-induced atherosclerosis). Supporting this
hypothesis, we demonstrated that sCX3CL1 is in fact an effi-
cient survival signal to monocytes. Thus, CX3CR1 expression
could participate not only by promoting cell-to-cell interac-
tions with an inflamed endothelium, but also by increasing Mo
survival.
Accordingly, the importance of the CX3CR1–CX3CL1 axis in
pathogenesis has been highlighted in several studies. It is
involved in atherosclerosis,26,41–42,45,46 vascular and renal
inflammation37,48,53 and cancer,50 it stimulates actin reorgan-
ization in microglia49,54 and it promotes leukocyte–renal
endothelial cell interactions during hemolytic uremic syn-
drome, thereby contributing to the renal microvascular dys-
function and thrombotic microangiopathy.55,56
To improve our understanding of the biological role of the
interaction between fractalkine and CX3CR1 in monocytic
populations, we analyzed CX3CR1 surface protein expression
as well as mRNA expression in freshly Mo, MAC and DC
populations.
Heterogeneity among human monocytes is well established.4
There are two main subsets, which include the ‘classical’
CD1411/CD162 and ‘non-classical’ CD141/CD161 mono-
cytes, both of which express CX3CR1. However, the CD14
1/
CD161 subset characteristically expresses higher levels.57
Although the CD141/CD161 subset expresses higher CX3CR1
levels, it is a very small population in healthy individuals, and it
shows considerable heterogeneity.4 We analyzed CX3CR1
expression during differentiation in the whole population of
peripheral human monocytes because the separate analysis of
the different subsets is technically impracticable due to the
complexity of these populations. Therefore, we observed that
CX3CR1 was rapidly downregulated during monocyte differ-
entiation. However, significant differences in CX3CR1 expres-
sion exist between DCs and MACs. Lower CX3CR1 cell surface
expression levels were observed from 24 h after differentiation
into DCs, and negligible CX3CR1 protein expression was
observed after 72 h of culture or during DC maturation.
Consistently, CX3CR1 mRNA was profoundly downregulated,
although it was not totally absent in DCs, suggesting differenti-
ation-associated downregulation both at the transcriptional and
translational level. In agreement with these results, there was no
protection against apoptosis mediated by sCX3CL1 in DCs,













































Figure 4 CX3CR1 gene expression in Mos and Mo-derived DCs and
MACs. Total RNA was prepared from freshly isolated Mo and cells that
had been cultured for three days with GM-CSF (50 ng/ml)1IL-4 or IL-13
(20 ng/ml) to differentiate Mo into iDCs (IL-4 DMo or IL-13 DMo), or for 7
days with GM-CSF (30 ng/ml) to differentiate Mo into MACs. MACs were
further cultured for 72 h either in presence of LPS (100 ng/ml) and IFN-
c (400 U/ml) to obtain classically activated MACs (M1), or IL-4 (25 ng/
ml) to obtain alternative-differentiated MACs (M2). Subsequently,
cDNA was prepared and real-time PCR was performed using specific
primers for V28 variant of CX3CR1 and GAPDH. (a) The specificity of
the primers is shown. PCR products obtained in the Mo were electro-
phoresed on 2% agarose gel and visualized with ethidium bromide
staining. M is a 100 bp DNA ladder. (b) CX3CR1 mRNA expression
in the different cell populations was analyzed by real-time RT-PCR.
Data were normalized against GAPDH gene expression. The results
are expressed in arbitrary units. Each bar represents mean6s.e.m. of
3–5 different donors, each one assessed in quadruplicate. *P,0.05,
**P,0.01, by the Kruskal–Wallis test (P,0.001) followed by the
Mann–Whitney U test. DC, dendritic cell; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; iDC, immature dendritic cell; GM-CSF,
granulocyte-macrophage colony stimulating factor; IFN, interferon;
MAC, macrophage; Mo, monocyte; RT-PCR, reverse transcriptase-
polymerase chain reaction.
CX3CR1 expression in monocytes during differentiation
CA Panek et al
8
Cellular & Molecular Immunology
which correlates with the absence of CX3CR1 expression.
Although some reports have addressed mRNA CX3CR1
expression in DCs, and a CX3CL1-dependent function, the cor-
responding protein has not been shown.39,58 In contrast, it has
been reported that DCs express the corresponding ligand, che-
mokine CX3CL1, which was increased during DC maturation
(particularly by CD40 ligation).20 Stable CX3CR1 expression
during the DC maturation process would contradict the mat-
uration state that is dependent on the expression of other CC-
chemokine receptors, which may ensure the directional traffic
of immature DCs from blood to target sites.59 The controversial
conclusion about CX3CR1 protein expression in DCs could be
derived from the presence of CX3CR1 mRNA, which was also
observed under our experimental conditions, or the use of DCs
from different origins or obtained through different purifica-
tion protocols. Conversely, and in line with the CX3CR1–
CX3CL1 survival signal hypothesis, DCs are generally short-
lived and are replaced by blood-bone precursors.60,61
Additionally, CX3CR1 downregulation may be involved in
restricting the ‘reverse migration’ of differentiated monocytes
back into the blood stream, thus facilitating capture within the
tissues. In contrast, MACs express intermediate CX3CR1 pro-
tein level and show a partial survival signal by sCX3CL1.
Moreover, CX3CR1 can be increased in MACs by IFN-c during
the classical activation pathway or when monocytes are exposed
to IFN-c early during the DC-differentiation protocol. It has





































































































Figure 5 Effect of soluble CX3CL1 (sCX3CL1) on the Mo, DC and MAC apoptotic rate. (a) Mos were cultured in medium with or without (control)
sCX3CL1, at the indicated concentration for 24 h at 37 uC. Apoptosis was measured by fluorescence microscopy, as indicated in the section on
‘Materials and methods’. Each bar represents the mean6s.e.m. from 3–5 different donors. **P,0.005, according to the Kruskal–Wallis test
(P,0.005) followed by the Mann–Whitney U test. (b) Apoptosis from Mos, iDCs or MACs was measured in parallel by flow cytometry as detailed in
the Materials and Methods. Representative PI vs. annexin V double dot plots of Mos, iDCs and MACs incubated in medium with or without (control)
sCX3CL1 (1 mg/ml), 24 h at 37 uC. Each bar represents the mean6s.e.m. of annexin V-positive cells for each population from 3–5 different donors.
*P,0.05, according to the Mann–Whitney U test. DC, dendritic cell; iDC, immature dendritic cell; MAC, macrophage; Mo, monocyte; PI, propidium
iodide.
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been shown that under these conditions, the stimulatory capa-
city of DCs are negatively regulated, leading to a tolerogenic
phenotype as assayed by cell surface molecule expression, an
altered transcriptional profile and cytokine production.62 In this
regard, intermediate levels of CX3CR1 expression between iDCs
and tolerogenic DCs could contribute to phenotypically distin-
guishing between these types of DC. Interestingly, the mech-
anism of IFN-c-mediated effects on monocyte-derived DCs
has been shown to involve the inhibition of STAT-6 phosphor-
ylation and the downregulation of membrane IL-4a chain sub-
unit expression.63 These results are in line with previous data
demonstrating that the overnight incubation of Mo in the pres-
ence of IFN-c blocks the downmodulation of CX3CR1 in Mo.
38
The only difference between MACs and DCs that are differen-
tiated from Mos was IL-4 signaling. Moreover, the alternative
differentiation of MACs that are mediated by this cytokine was
also accompanied by the downregulation of CX3CR1 surface
expression and mRNA levels. Therefore, these data suggest that
the differential CX3CR1 expression on MACs and DCs might be
IL-4-dependent. IL-4 binds to the high-affinity IL-4Ra and then
heterodimerizes with either the common c chain (cC) or the IL-
13Ra1 chain, forming type I and type II receptor complexes,
respectively.64 IL-13, however, binds with relatively low affinity
to the IL-13Ra1 chain and then heterodimerizes with the IL-4Ra
chain to form a type II receptor complex. Ligand engagement of
receptor complexes activates Janus kinases (JAKs) associated
with the cytoplasmic domains of the different chains. JAK3 is
constitutively associated with cC through interactions with
canonical box 1 and box 2 sequence motifs (JAK-binding
motifs). The activated kinases initiate downstream signaling cas-
cades that recruit substrate proteins, such as IRS-1 (in non-
hematopoietic cells) or IRS-2 (in hematopoietic cells), STAT6
and others, for tyrosine phosphorylation by the JAKs.65
IL-4 produced by Th2 lymphocytes is known to exert anti-
inflammatory effects on Mos or MACs. IL-4 acts through
activation of the Jak/STAT signaling pathway and inhibits
release of pro-inflammatory cytokines by Mo.66 Our data dem-
onstrate that IL-4 also rapidly downregulates the expression of
CX3CR1 mRNA, accompanied by a decrease in the cell surface
expression of this receptor. The latter may somewhat precede
that of the mRNA, suggesting that regulation at the translation
level may also be involved. The negative regulation of CX3CR1
by IL-4 points to opportunities for the therapeutic modulation
of CX3CR1 expression.
Under the rationale that IFN-c and IL-4/IL-13-dependent
signals oppositely regulate CX3CR1 mRNA and protein expres-
sion, it is important to consider that both cytokines are the
major exponents of Th1 and Th2 responses, respectively.
Recent evidence indicates that receptor expression determines
the spectrum of action of chemokines in Th1 and Th2 cells and
that CX3CR1 is preferentially expressed on the former, which is
consistent with the observation that Th1 cells, but not Th2 cells,
respond to CX3CL1.
67
Interestingly, a Th1 cytokine pattern predominates in
inflammatory situations that drive expansion of Th1 cells,
and by acting as both an adhesion molecule and a chemoat-
tractant, CX3CL1 recruits monocytes, NK cells and T lympho-
cytes to the endothelium. The present results further support
the hypothesis that fractalkine (CX3CL1) is involved in an
amplification circuit of polarized Th1 responses68 by prolong-
ing the half-life of CX3CR1 positive cells.
Conversely, Th2 cytokines, such as IL-4 and IL-13, induce an
‘alternative’ activation program (M2) in MACs. M2 MACs
dampen inflammatory and adaptive Th1 responses by pro-
ducing anti-inflammatory factors (IL-10, transforming growth
factor-b and IL-1 receptor antagonist) by scavenging debris
and by promoting angiogenesis, tissue remodeling and repair.
Recently, the knowledge about MAC plasticity has been
enlarged through transcriptome-based network analysis, dem-
onstrating differences inside those so-called ‘alternatively acti-
vated’ MACs (M2a, M2b and M2c) and the capacity to switch
from an activated M1 state back to one of the M2 states, and
vice versa, upon specific signals.69,70 In line with this study, the
present work would contribute to define MAC activation pro-
files and to the development of new therapeutic strategies in
human disease.
Though the actual physiological role of the differential
expression of CX3CR1 in the cell membrane of Mo-derived
cells is incompletely understood, the results presented herein
suggest that Mo differentiation and the antagonistic regulatory
capacity of IFN-c and IL-4 offer an additional way to control
cell survival and function. Thus, by improving our understand-
ing of the regulatory mechanisms that govern CX3CR1 express-
ion on monocyte lineage cells, we can better appreciate how
monocyte recruitment, survival and activation are controlled
during the immune response.
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